Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia
|ClinicalTrials.gov Identifier: NCT00735813|
Recruitment Status : Completed
First Posted : August 15, 2008
Last Update Posted : September 5, 2012
|Condition or disease||Intervention/treatment||Phase|
|Bacteremia Neoplasms||Device: Taurolock Device: Heparin||Phase 3|
The most frequent complications of long term TCVC are catheter related blood steam infections(CRBSI)often caused by microorganisms located in the biofilm formed on the inner surface of the TCVC after a short time. CRBSI may be lifethreatening, will need long term intravenous broad spectrum antibiotic therapy possibly combined with intraluminal antibiotic lock therapy. In spite of this CRBSI may often lead to the premature removal of the TCVC.
Several methods to prevent the occurrence of intraluminal microbial colonization have been investigated with no single method standing out as the optimal one.
There is a need for a simple and safe method of reducing the occurrence of CRBSI in immunocompromised children receiving chemotherapy for malignant diseases. Various catheter lock solutions in stead of using heparin have been investigated in experimental models. Taurolidine is a chemically modified amino acid with broad spectrum antimicrobial activity in vitro. It is claimed to prevent the formation of luminal biofilm in TCVCs in a CVC model and it has been demonstrated to eradicate infected CVC in a three reports with a total of 18 patients.
In a 24 months study of routine use of Taurolidine 1,25%/Sodium-Citrate 4% (TaurolockTM) a reduction of gram-positive CVC associated infections was demonstrated. The findings were not statistically significant due to relatively few patients.
There is a need of a larger study with more patients receiving Taurolock for locking the TCVC between use in order to test for a significant reduction of the occurrence of CRBSI. Furthermore there is a need for an in vivo demonstration of the reduction of biofilm formation in TCVCs locked with taurolock compared with TCVCs locked with heparin.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||129 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2012|
Tunneled central venous catheters locked with Taurolock
When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
Active Comparator: B
Tunneled central venous catheter locked with heparin
When not in use the childrens tunneled central venous catheters are locked with heparin
- Number of catheter related blood stream infections(CRBSI)in the Taurolock group vs the heparin group. Number of CRBSI/1000 CVC days in the Taurolock group vs the heparin group. Number of CVCs removed in the Taurolock group vs the heparin group [ Time Frame: November 2010 ]
- Biofilm formation in the CVCs treated with Taurolock compared with the biofilm formation in the CVCs treated with heparin [ Time Frame: February 2010 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00735813
|Childrens Department of Oncology A4, Aarhus Universityhospital, Skejby|
|Århus N, Denmark, 8200|
|Study Director:||Henrik Schrøder, MD, Dr.med.||Aarhus Universityhospital, Skejby|